Rodman & Renshaw analyst Elemer Piros initiated coverage of Tharimmune (THAR) with a Buy rating and $17 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THAR:
- Tharimmune presents clinical data on TH104 for chronic pruritus
- Tharimmune granted patent for delivery of molecularly targeted therapeutics
- Tharimmune receives regulatory feedback from EMA for TH104 program
- Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
